Acute bacterial meningitis causes a substantial number of deaths in Cameroon. Among 170 children with acute meningitis, 112 were positive for a bacterial pathogen when tested using polymerase chain reaction amplification, and Streptococcus pneumoniae accounted for 57.1% of cases. Pneumococcal serotype coverage by 13-valent pneumococcal conjugate vaccine was 62.1%. This study shows that in Camer...

The aim of this study was to compare the immunologic response to a prime-boost immunization strategy combining the 13-valent conjugate pneumococcal vaccine (PCV13) with the 23-valent polysaccharide pneumococcal vaccine (PPSV23) versus the PPSV23 alone in HIV-infected adults. HIV-infected adults were randomized to receive PCV13 at week 0 followed by PPSV23 at week 4 (n = 31, prime-boost group) o...

Streptococcus pneumoniae is the most common cause of bacterial pneumonia worldwide and a leading cause of sepsis and meningitis. In the United States, an estimated 40,000 persons die each year from pneumococcal infections. Since 1983, 23-valent pneumococcal polysaccharide vaccines have been licensed in the United States and are 56%-57% effective in preventing invasive pneumococcal disease. Howe...

The number of notified cases of invasive pneumococcal disease (IPD) in the 2nd quarter of 2016 was substantially more than the previous quarter and marginally more than the number of notified cases in the 2nd quarter of 2015. Overall, the decline in disease due to the serotypes targeted by the 13-valent pneumococcal conjugate vaccine (13vPCV) has been maintained across all age groups, since the...

A new, 13-valent pneumococcal conjugate vaccine (PCV13, Prevnar 13), from Wyeth Pharmaceuticals was licensed by the US Food and Drug Administration (FDA) in February for use in all children ages 6 weeks to 59 months. Th e new vaccine was licensed for the prevention of invasive pneumococcal disease (pneumonia, meningitis, and bacteremia) and otitis media. PCV13 is meant to replace the 7-valent P...

The number of notified cases of invasive pneumococcal disease (IPD) in the 4th quarter of 2015 was fewer than the previous quarter and less than the number of notified cases in the 4th quarter of 2014. Overall, the decline in disease due to the serotypes targeted by the 13-valent pneumococcal conjugate vaccine (13vPCV) has been maintained across all age groups, since the 13vPCV replaced the 7-v...

In Republic of Korea, a 7-valent pneumococcal conjugated vaccine (PCV7) was licensed for use in infants in 2003, and 13-valent PCV (PCV13) replaced it since 2010. We investigated trends in serotype distribution and antibiotic susceptibility of pneumococcal isolates from adult patients with invasive pneumococcal diseases (IPD). Invasive pneumococcal isolates from adult patients of ≥ 16 years of ...

The number of notified cases of invasive pneumococcal disease (IPD) in the 1st quarter of 2016 was substantially fewer than the previous quarter and marginally less than the number of notified cases in the 1st quarter of 2015. Overall, the decline in disease due to the serotypes targeted by the 13-valent pneumococcal conjugate vaccine (13vPCV) has been maintained across all age groups since the...

This piece summarizes the presentations and discussions at a meeting on pneumococcal disease surveillance in the Americas that was held in Mexico City, Mexico, on 2 November 2004. This meeting was organized by the Pan American Health Organization (PAHO) and the Pneumococcal Vaccines Accelerated Development and Introduction Plan (PneumoADIP) of the Global Alliance for Vaccines and Immunization (...